William J.
- Country
- France
- Department
- Medical Oncology Service
Research Overview
- Efficacy and Safety of Inavolisib plus Combination Therapy in Patients with Endocrine-Resistant HR+/HER2- Advanced Breast Cancer with Chromosome 8p Loss
- Comparison of RO7771950 plus combination therapy versus tucatinib plus combination therapy in pretreated HER2-positive locally advanced or metastatic breast cancer
- Phase 3 Randomized Study of BGB‑43395 + Letrozole versus CDK4/6 Inhibitor Combination + Letrozole in Treatment‑Naïve Advanced HR+/HER2‑ Breast Cancer
Data & Insights
Has run more than one trial at 224 of 438 partner sites.
Specializations
Breast Cancer and Hormone Receptor-Positive Disease
William Jacot’s clinical research is strongly centered on breast cancer, with particular involvement in HER2-negative, HER2-low, and triple-negative breast cancer, as well as ER-positive and metastatic presentations. His work also extends to early breast cancer, adjuvant endocrine therapy, and biomarker-driven treatment selection.
- Metastatic breast cancer
- Triple-negative breast cancer
- HER2-negative and HER2-low disease
- Endocrine-resistant and PIK3CA-mutated breast cancer
- ctDNA-guided and biomarker-selected strategies
The therapeutic focus includes targeted therapy, antibody-drug conjugates, and endocrine-based treatment across advanced and recurrent disease settings.
Thoracic Oncology and Head and Neck Cancer
His research landscape includes a broad commitment to non-small cell lung cancer, small cell lung cancer, and head and neck squamous cell carcinoma, covering both locally advanced and metastatic disease. He is also involved in studies addressing esophageal and gastroesophageal junction malignancies.
- Non-small cell lung cancer with actionable alterations
- Small cell lung cancer
- Head and neck squamous cell carcinoma
- Esophageal and gastroesophageal junction adenocarcinoma
- Radiotherapy-based and immunotherapy-based approaches
These activities reflect interest in treatment strategies for locoregional control, recurrent disease, and metastatic progression.
Gynecologic Oncology
William Jacot is active in gynecologic cancers, with emphasis on ovarian cancer, endometrial cancer, cervical cancer, and related rare histologies. His trial portfolio also includes fallopian tube and primary peritoneal cancer, alongside molecularly defined subgroups.
- Ovarian cancer and primary peritoneal cancer
- Endometrial cancer
- Cervical cancer
- Carcinosarcoma and uterine sarcoma
- Platinum-sensitive and platinum-resistant disease
The therapeutic domains include maintenance therapy, immunotherapy, and PARP inhibitor-based strategies in advanced and recurrent settings.
Gastrointestinal, Urologic, and Hepatobiliary Cancers
His research also spans a wide range of digestive tract and urinary tract malignancies, including colorectal cancer, gastric cancer, pancreatic cancer, biliary tract cancer, and urothelial carcinoma. This area includes both unresectable and metastatic disease as well as selected resectable tumor settings.
- Colorectal cancer
- Gastric and gastroesophageal cancer
- Pancreatic adenocarcinoma
- Biliary tract cancer
- Urothelial carcinoma
His therapeutic interests include systemic anticancer therapy, perioperative treatment, and molecularly guided treatment selection.
Rare Tumors, Sarcomas, and Central Nervous System Tumors
Another key area of involvement is rare cancer management, including soft tissue sarcoma, osteosarcoma, chondrosarcoma, mesothelioma, neuroendocrine tumors, and selected central nervous system tumors such as glioblastoma and diffuse midline glioma.
- Soft tissue sarcoma and osteosarcoma
- Mesothelioma
- Neuroendocrine tumors
- Glioblastoma and diffuse midline glioma
- Rare and molecularly defined solid tumors
The therapeutic scope includes precision oncology, immunotherapy, and approaches for advanced solid tumors with limited standard options.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.